Our purpose

We aim to make a difference in patient care through our cutting-edge nanotechnology.
We believe that our rapid, laboratory-quality diagnostic solutions enable physicians to make early, appropriate clinical decisions at the point of need.


Our facilities

Abionic is ISO 13485 certified since 2012. Our abioSCOPE system and tests meet IVD standards.
Our manufacturing line has been designed to meet the highest international medical standards with a current capacity of 1 million tests produced annually.
Discover
ISO Certificate


Our team

In less than 10 years, we have demonstrated our ability to bring the company to a stage of full expansion. Currently, our team is composed of 50+ highly skilled employees.
Our dynamic team is highly effective, and we are committed to changing the world of in vitro diagnostics (IVD) by bringing rapid diagnostic solutions close to the patient.


Our workplace

We are committed to creating a positive workplace environment and a culture of trust that support dedicated teamwork.
We believe that the success of a company strongly relies on the happiness of its team members.
"At Abionic we can easily see the impact of our work on the company's growth and this is very motivating". Stéphane Broillet, Head of Engineering.
"What I like most here is the working atmosphere, it's very dynamic and it motivates me to do my best, learn and grow quickly". Alison Papaux, R&D Biology Technician.

Events

Medica 2022
Booth:
Abionic Booth

Mon, 14 Nov 2022 - Thu, 17 Nov 2022


Stockumer Kirchstrasse 61
Messplatz, 40474
Germany

News

Practical Implementation of the Pancreatic Stone Protein Sepsis Test

2022 25 May

An overview of a discussion on sepsis and the Pancreatic Stone Protein (PSP) biomarker by Dr João Pereira, Hospital De Vila Franca De Xira, Portugal and how it can be used for early diagnosis of sepsis and facilitate decision-making regarding the administration of antibiotics. The discussion was chaired by Prof Pedro Póvoa, coordinator of... Read more

Abionic Webinar - Advancing the Diagnosis of Sepsis in the Intensive Care Units

2021 04 Oct

Real world evidence on the practical implementation of the Pancreatic Stone Protein (PSP) Sepsis Test   On the 22nd of September, attendees tuned in to a lively discussion on sepsis chaired by Professor Pedro Póvoa, who is currently coordinator of the Intensive Care Unit (ICU) in one of the largest hospitals in Lisbon and who is no stranger to the... Read more

Pancreatic Stone Protein found to be an Early Marker for Risk Stratification in Acute Pancreatitis

2021 28 Jul

Context Growing numbers of obesity, alcohol abuse and gallstones are leading to an increase in the incidence of acute pancreatitis. This sudden inflammatory disease of the pancreas usually requires hospitalization due to high mortality and morbidity rates. In some cases, acute pancreatitis can progress to severe pancreatitis, which is characterized... Read more

New Data Confirms the Clinical Benefit of PSP for the Diagnosis of Severe Infections

2021 28 May

Critical Care, the top-ranked open access journal in the field of critical care medicine, published the results of a study led by Lausanne University Hospital’s Dr Philippe Eggimann and Bern University Hospital’s Dr Yok-Ai Que this month [1]. The authors analyzed pooled data from five cohorts showing that the Pancreatic stone protein (PSP) biomarker... Read more

The PSP Biomarker Rises Earlier than CRP and PCT in Sepsis, a New Study Shows

2021 20 Apr

Sepsis is a global healthcare problem, with 50 million cases each year and 11 million related deaths  1 . It’s the life-threatening complication of an infection, in which the host’s immune response to a pathogen damages its own organs. The clinical diagnosis of sepsis relies mostly on signs and symptoms that are neither sensitive nor specific enough... Read more

Great Symposium on the PSP Sepsis Biomarker - Hosted By Abionic and Palex at the GALISEPSIS 2021

2021 08 Apr

On April 6th, Abionic and Palex joined forces to participate in the first day of GaliSepsis, the National Sepsis Course hosted and organized virtually by the Ourense University Hospital Complex (CHUO) in Spain. With the aim of updating the most important concepts and reviewing the latest developments in the management of patients with sepsis, three... Read more

Jobs not available

Catalogue

    Catalogue not available

Biopôle, Alanine Building, Route de la Corniche 5
Epalinges
CH-1066
Switzerland
+41 21 353 33 80

White Papers - Case Studies

Pancreatic Stone Protein (PSP) Sepsis Test on the Abioscope® Point-Of-Care Platform

2022 06 Jun

1. Sepsis: the Need for Speed Sepsis is a life-threatening form of organ dysfunction caused by a dysregulated host response to infection 1 . This extremely heterogeneous and dynamic syndrome is the result of complex interactions between invading microorganisms and the host’s immune system. Disruption of the host’s ability to maintain immune homeostasis... Read more

Abionic's Unique Sepsis Detection Solution

2022 21 Apr

Based in Switzerland, Abionic is an in vitro diagnostic company, uniquely positioned at the intersection of medical technology, biotechnology and nanotechnology. The company has developed an unparalleled nanofluidic technology-based platform, the abioSCOPE® to offer patients fast blood test results right at the Point-of-Care (PoC). The abioSCOPE® is... Read more

Videos

    Videos not available

Articles

Practical Implementation of the Pancreatic Stone Protein Sepsis Test

2022 25 May

An overview of a discussion on sepsis and the Pancreatic Stone Protein (PSP) biomarker by Dr João Pereira, Hospital De Vila Franca De Xira, Portugal and how it can be used for early diagnosis of sepsis and facilitate decision-making regarding the administration of antibiotics. The discussion was chaired by Prof Pedro Póvoa, coordinator of... Read more

Blog

Not available

Find Abionic on Social Media